Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Apeiron Begins PI Study of Neuroblastoma Immunotherapy Agent in Japan
July 10, 2014
- Vital-Net Makes Miyagi-Based Dispensing Pharmacy Chain Ohno its Subsidiary
July 10, 2014
- Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
- MTPC to Up Japan Sales Force by 200-300 Partly via Job Transfers
July 9, 2014
- 31 Executives Received Annual Compensations for FY2013 of Over 100 Million Yen: Jiho Survey
July 9, 2014
- MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
- Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
- Sanofi’s Prostate Cancer Drug Cabazitaxel Gets Japan OK
July 7, 2014
- MTPC’s SGLT-2 Inhibitor Canaglu Wins Japan Approval
July 7, 2014
- European Commission Approves Expanded Indication for Halaven for Earlier Use in Breast Cancer Treatment: Eisai
July 7, 2014
- Nippon Kayaku Obtains Approval for Remicade Biosimilar
July 7, 2014
- Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
- Santen to Complete Acquisition of Ophthalmology Assets from Merck
July 4, 2014
- Taiho Submits Application for Additional Indication of Febrile Neutropenia for Zosyn
July 4, 2014
- BMKK Asks Major Law Firm to Conduct Independent Investigation of Clinical Research on Sprycel
July 4, 2014
- Kyowa Kirin to Resume Development of Bardoxolone Methyl for CKD Patients with Type 2 Diabetes
July 4, 2014
- Poteligeo Re-Filed for Approval of Additional Indication of Untreated CCR4-Positive ATL
July 3, 2014
- Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
July 3, 2014
- Genzyme Japan Submits NDA for Oral Gaucher’s Disease Drug
July 3, 2014
- CMIC, JSR Set Up Joint Venture for Next-Generation Antibodies
July 3, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…